{"nctId":"NCT00149799","briefTitle":"Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder","startDateStruct":{"date":"2005-05"},"conditions":["Anxiety Disorders","Somatoform Disorders"],"count":100,"armGroups":[{"label":"Escitalopram","type":"EXPERIMENTAL","interventionNames":["Drug: Escitalopram"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Escitalopram","otherNames":["Lexapro"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatient men and women age 18 and older\n* Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)\n* Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale\n* Lives within driving distance of Boston, MA or Providence, RI\n\nExclusion Criteria:\n\n* Suicidal or homicidal tendencies\n* Alcohol/drug abuse or dependence within 3 months of study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Phase II Relapse of Body Dysmorphic Disorder (BDD) Symptoms (as Measured by the BDD-YBOCS)","description":"We compared the rate of relapse (accounting for time from randomization to relapse and censoring) by treatment arm in Phase II.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase I Response to Escitalopram (as Measured by the BDD-YBOCS)","description":"We calculated the proportion of patients who achieved response in Phase I, defined as a \\>=30% reduction in BDD-YBOCS total score from baseline through the last phase 1 visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Depression Symptoms (HAM-D) During the Double-blind Relapse Prevention Phase of the Trial (Phase II)","description":"Depressive symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D), a widely used 21-item depression scale. Of the 21 items on the scale, only the first 17 are used to calculate the total score. Eight of these items are scored on a 5-point scale, ranging from 0 (not present) to 4 (severe symptom), and nine are scored from 0-2. The total score ranges from 0 to 50, where higher scores indicate a greater severity of depression and scores greater than 19 are generally considered indicative of severe depression.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5357143","spread":"4.4010280"},{"groupId":"OG001","value":"3.3793103","spread":"3.3744184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8928571","spread":"4.1840906"},{"groupId":"OG001","value":"4.2333333","spread":"3.9799786"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2857143","spread":"5.5099717"},{"groupId":"OG001","value":"6.3703704","spread":"6.4875511"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8461538","spread":"5.5403416"},{"groupId":"OG001","value":"5.4285714","spread":"4.7798076"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2307692","spread":"3.5922995"},{"groupId":"OG001","value":"3.7407407","spread":"3.0457106"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.625","spread":"3.3337862"},{"groupId":"OG001","value":"3.7727273","spread":"3.0539875"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8695652","spread":"4.0486176"},{"groupId":"OG001","value":"4.04","spread":"3.8457769"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"5.0259327"},{"groupId":"OG001","value":"4.4090909","spread":"3.4731499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"3.9373381"},{"groupId":"OG001","value":"4.5454545","spread":"4.0676104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9565217","spread":"3.067102"},{"groupId":"OG001","value":"4.2","spread":"4.007887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.375","spread":"3.2412088"},{"groupId":"OG001","value":"4.7","spread":"4.5664682"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0416667","spread":"3.9943348"},{"groupId":"OG001","value":"5.4","spread":"5.2555735"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8181818","spread":"3.8623502"},{"groupId":"OG001","value":"3.4666667","spread":"3.8705235"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2400000","spread":"4.8500859"},{"groupId":"OG001","value":"4.1578947","spread":"5.0250833"}]}]}]},{"type":"SECONDARY","title":"Change in Functional Impairment Symptoms (LIFE-RIFT) Over Double-blind Relapse Prevention Phase of the Trial (Phase II)","description":"Subjects switched to placebo were compared to those remaining on escitalopram (double-blind randomization) to assess functional impairment as measured by the Longitudinal Interval Followup Evaluation - Range of Impaired Functioning Tool (LIFE-RIFT). The tool assesses psychosocial functioning in multiple domains, consisting of 5- to 7-point clinician administered scales that obtain information about work, household duties, student work, relationships with family and friends, recreation, life satisfaction, and global social adjustment. Scores can range from 3-22 with higher scores indicating poorer functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0000000","spread":"2.6943013"},{"groupId":"OG001","value":"8.2413793","spread":"2.3551641"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8000000","spread":"3.3040379"},{"groupId":"OG001","value":"9.0000000","spread":"2.7961012"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7600000","spread":"3.6887215"},{"groupId":"OG001","value":"8.8947368","spread":"3.1428002"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life (Q-LES-Q-SF) Over Double-blind Relapse Prevention Phase of the Trial (Phase II)","description":"Subjects switched to placebo were compared to those remaining on escitalopram (double-blinded randomization) to assess quality of life changes as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF). The Q-LES-Q-SF is designed to help assess the degree of enjoyment and satisfaction experienced during the past week across several domains: social, leisure, household, work, emotional well-being, physical, and school; it consists of 5-point rater-administered questions. Raw scores can range from 14-70, which are converted to percentage maximum possible by calculating: % Max = (Raw-minimum score)/(maximum score-minimum score). Q-LES\\_Q-SF percent scores can range from 0-100, with higher scores indicating greater quality of life and satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1785714","spread":"12.9930282"},{"groupId":"OG001","value":"70.9259259","spread":"16.0166402"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2727273","spread":"14.1528453"},{"groupId":"OG001","value":"67.3684211","spread":"16.0665648"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0833333","spread":"18.5376624"},{"groupId":"OG001","value":"68.6470588","spread":"15.2436100"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Headache","Fatigue","Insomnia","Nausea","Sexual Dysfunction"]}}}